STERIS to acquire Xodus Medical for $2.1bn in surgical safety deal
STERIS plc has agreed to acquire Xodus Medical, a specialty surgical products business headquartered near Pittsburgh, Pennsylvania, for $2.1 billion at closing. The Dublin-listed company, which trades on the NYSE under the ticker STE, expects to realise cash tax benefits with a net present value of approximately $300 million, bringing the effective net purchase price to around $1.8 billion. An earnout provision of up to $150 million is tied to Xodus Medical hitting specified performance targets in calendar year 2028.
Xodus Medical is projected to generate approximately $245 million in annual revenue for 2026, with adjusted EBIT of around $135 million, equating to a margin of roughly 55 per cent on that measure. The transaction is to be financed primarily with debt and is expected to close by 31 December 2026, pending customary regulatory approvals. STERIS said it will update its fiscal 2027 financial outlook to include Xodus Medical once the deal closes.
Strategic rationale
Founded in 1993, Xodus Medical develops and manufactures perioperative safety products sold into hospital operating rooms worldwide. Its flagship offering is the Pink Pad patient positioning system, a proprietary line designed to reduce pressure injuries and improve staff ergonomics during surgery. STERIS is positioning the acquisition as a natural extension of its existing healthcare consumables business, with the combined portfolio addressing infection prevention, sterilisation and, now, intraoperative patient safety.
Dan Carestio, president and chief executive of STERIS, described Xodus Medical as a business that has demonstrated "double-digit" revenue growth, supported by a pipeline of new products and what he characterised as a highly effective commercial team. Craig Kaforey, chief executive of Xodus Medical, said joining STERIS would allow the company to deliver greater value to its hospital customers and expand professional opportunities for its employees.
Goldman Sachs is advising STERIS on the transaction, with Jones Day as legal counsel. J.P. Morgan is advising Xodus Medical, with Morgan, Lewis and Bockius serving as legal adviser.
Market context
The acquisition reflects a broader trend in the medical device and surgical supply sector, where large, diversified players are consolidating around product categories that generate recurring consumable revenue. Consumables are typically valued more highly than capital equipment because they command predictable, high-frequency reorder cycles and are less exposed to hospital capital expenditure freezes.
Patient and staff safety in the operating room has become an increasingly active product category. Regulatory scrutiny of hospital-acquired pressure injuries has intensified in several markets, and value-based care models in the United States incentivise hospitals to reduce preventable complications. These dynamics improve the commercial case for positioning products and similar perioperative safety accessories.
STERIS's move also reflects continued consolidation pressure in the infection prevention and surgical supply space, where competitors including Getinge and Fortive's Provation portfolio have similarly expanded through acquisition. At a revenue multiple of roughly 8.6 times on the 2026 projection, the deal pricing signals confidence in Xodus Medical's growth trajectory, though the earnout structure suggests STERIS is managing downside risk on the 2028 performance assumptions.